ScreenerHero

CRNX Crinetics Pharmaceuticals Inc

NAS · US · Healthcare · Biotechnology · crinetics.com
84.95USD0.00%Mkt Cap: 9.01B $P/E: —

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap9.01B USD
Enterprise Value7.85B USD
Revenue (TTM)42.16M USD
Gross Profit6.62M USD
Net Income (TTM)-465.32M USD
Revenue/Share0.42 USD
Last Price84.95 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees594
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS22663K1079
Valuation
P/E (Trailing)—
P/E (Forward)-21.17
PEG—
EV/EBITDA-14.41
EV/Revenue186.25
P/S213.80
P/B7.54
EPS (TTM)-5.05
EPS (Forward)-4.12
52W Range
30.00100% of range85.01
52W High85.01 USD
52W Low30.00 USD
Profitability
Gross Margin86.02%
Oper. Margin-527.35%
EBITDA Margin0.00%
Profit Margin-6046.22%
ROE-46.90%
ROA-41.32%
Growth
Revenue Growth2336.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-377.92M USD
CapEx (TTM)5.76M USD
FCF Margin-590.10%
FCF Yield-2.76%
Net Debt-1.16B USD
Net Debt/EBITDA2.13
Balance Sheet
Debt/Equity0.05
Current Ratio15.57
Quick Ratio15.24
Book Value/Sh11.27 USD
Cash/Share11.37 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)85.00 USD
Upside (mean)+0.1%
Target Range85.00 USD – 85.00 USD
# Analysts8
Ownership
Shares Out.106.10M
Float95.50M
Insiders1.13%
Institutions119.21%
Short Interest
Short Ratio2.3d
Short % Float7.26%
Short % Out.6.21%
Shares Short6.59M
Short (prev mo.)6.21M
Technical
SMA 5076.93 (+10.4%)
SMA 20050.87 (+67.0%)
Beta0.09
S&P 52W Chg16.45%
Avg Vol (30d)2.37M
Avg Vol (10d)2.40M
Technical Indicators
RSI (14)90.4
MACD2.9108
MACD Signal3.9233
MACD Hist.-1.0125
BB Upper85.33 USD
BB Middle84.43 USD
BB Lower83.54 USD
BB Width2.13%
ATR (14)0.4783 USD
Vol Ratio (20d)0.00x